UID:
almahu_9948025961202882
Format:
1 online resource (297 p.)
ISBN:
1-281-05383-X
,
9786611053833
,
0-08-052595-4
,
1-4356-0513-6
Content:
This book is the first definitive overview on adenosine receptor antagonists and their application to the treatment of Parkinson's Disease. The effect of these novel non-dopamine drugs on vitro and in vivo systems clearly shows their potential for the treatment of this debilitating disease. This book covers how the Parkinson's disease antagonist drug, A2A, has been researched, developed, and tested. It is an essential book for researchers interested in the basal ganglia, purine biology, and Parkinson's Disease.Key Features* Discusses the discovery and development of a
Note:
Description based upon print version of record.
,
Front Cover; Adenosine Receptors and Parkinson's Disease; Copyright Page; Contents; Contributors; Preface; Chapter 1. Introductory Remarks: Adenosine A2A Receptor Antagonists: A Novel Approach to the Treatment of Parkinson's Disease; I. A View of the Action of Adenosine in the Striatum; References; Chapter 2. Localization of Adenosine Receptors in Brain and Periphery; I. Adenosine; II. Receptor Subtypes; III. Summary; References; Chapter 3. Medicinal Chemistry of Adenosine Receptors in Brain and Periphery; I. Introduction; II. A1 Adenosine Receptor Antagonists
,
III. A2A Adenosine Receptor AntagonistsIV. Conclusion; References; Chapter 4. Overview of the Physiology and Pharmacology of Adenosine in the Peripheral System; I. Metabolism, Receptors, and Modulation of Adenosine; II. Peripheral Nervous System; III. Cardiovascular System; IV. Renal Effects; V. Respiratory and Pulmonary System; VI. Gastrointestinal System; VII. Inflammation and Immune System; VIII. Endocrine and Exocrine Effects; IX. Concluding Remarks; References; Chapter 5. Biochemical Characterization of Adenosine Agonists and Antagonists; I. Introduction
,
II. Ligands for Adenosine Receptor SubtypesIII. Signal Transduction; IV. Biochemical Basis of the Use of A2A Antagonists in Parkinson's Disease; V. Conclusion; References; Chapter 6. Physiology of Adenosine Receptors in the Striatum; I. Introduction; II. Striatal Cell Subtypes; III. The Striatal Medium Spiny Neurons; IV. A2A Receptor-Mediated Suppression of GABAergic Transmission onto Medium Spiny Neurons; V. Adenosine Receptor Modulation of Glutamatergic Synaptic Transmission in the Striatum; VI. Influence of Adenosine Receptor Activation on Membrane Properties of Medium Spiny Neurons
,
VII. Antiparkinsonian Effects of A2A Receptor AntagonistsVIII. Conclusion; References; Chapter 7. Regulation of Neurotransmitter Release in Basal Ganglia by Adenosine Receptor Agonists and Antagonists in Vitro and in Vivo; I. Introduction; II. Methodology; III. The Adenosine A1 Receptor in the Basal Ganglia; IV. The Adenosine A2 Receptors in the Basal Ganglia; V. Relevance of the A2A Receptor to the Therapy of Parkinson's Disease; References; Chapter 8. Control of Gene Expression in Basal Ganglia by Adenosine Receptors; I. Introduction
,
II. Effect of CGS15943A on Proenkephalin mRNA Levels in Dopamine-Depleted StriatumIII. Effect of A2 and A1 Adenosine Receptor Antagonism on Levels of Striatal Peptide Gene Expression; IV. Discussion; References; Chapter 9. Knockout Mice in the Study of Dopaminergic Diseases; I. Introduction; II. D2-like Receptors; III. D1-like Receptors; IV. Dopamine D1 and D2 Receptor Interactions in Basal Ganglia; V. Dopamine and Adenosine; VI. D2 Receptor-Deficient Mice; VII. Adenosine A2A Receptor-Deficient Mice; VIII. Animal Models of Neuropathologies: D2 Receptor-Deficient Mice and Parkinson's Disease
,
References
,
English
Additional Edition:
ISBN 0-12-400405-9
Language:
English
